Investing Profile

Jim Tananbaum

VC

Photo of Jim Tananbaum, Managing Partner at Foresite Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Harvard Business School Network
263 CONNECTIONS
Massachusetts Institute of Technology Network
104 CONNECTIONS
Yale University Network
84 CONNECTIONS
Sierra Ventures Network
11 CONNECTIONS
cb
Foresite Capital Managing Partner
9
$668M
CompanyStageDateRound SizeTotal Raised
Insitro
Series AMay 2018
$543M
Co-investors: Vijay Pande (Andreessen Horowitz), Krishna Yeshwant (GV)
Juvenescence
Seed RoundJan 2018$12.3M
$12.3M
DNAnexus
Series EJan 2018$58M
$89.6M
Co-investors: Jeff Clavier (Uncork Capital), Manu Kumar (K9 Ventures), Krishna Yeshwant (GV), Nat Goldhaber
LifeMine Therapeutics
Series ASep 2017$55M
$55M
Co-investors: Krishna Yeshwant (GV)
Aimmune Therapeutics
Series BMar 2015$80M
$80M
Co-investors: Stacey Seltzer (Aisling Capital)
Tarsa Therapeutics
Series BMay 2014$7M
Series BMar 2012$28M
$35M
Intarcia Therapeutics
Series DApr 2014$200M
$558M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Bryan Roberts (Venrock)
Sequenta
Series CJul 2013$20M
$41.5M
Co-investors: Bill Ericson (Wildcat Ventures), Farzad Nazem
Founder and CEO Foresite Capital Management2010 - Present
Co-Founder and Managing Director PVP2 & PVP3 Prospect Venture Partners2001 - 2010
Co-Founder and Chief Executive Officer Theravance (THRX)1997 - 2000
Partner Sierra Ventures1993 - 1997
Co-Founder and CEO GelTex (acquired by Genzyme for $1.6 B)1991 - 1992
Harvard Business School mba
Harvard Medical School Doctor of Medicine (MD)
Massachusetts Institute of Technology Master of Science (M.S.) HST - information theory
Yale University BS BSEE, Math, computer science